Document Detail

Large-scale manufacture of peptide therapeutics by chemical synthesis.
MedLine Citation:
PMID:  12815383     Owner:  NLM     Status:  MEDLINE    
The large-scale commercial production of a 36-amino-acid peptide by chemical synthesis has been demonstrated in the development of enfuvirtide (T-20 or Fuzeon), a first-in-class membrane fusion inhibitor for the treatment of HIV. The rationale behind route selection and the scale-up of the process used to manufacture enfuvirtide are discussed.
Brian L Bray
Related Documents :
10692303 - Backbone dipoles generate positive potentials in all proteins: origins and implications...
20024133 - Development of a new microwave-assisted cleavable backbone amide linker (bal): a compar...
1517723 - Are papanicolaou smears enough? acetic acid washes of the cervix as adjunctive therapy:...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Nature reviews. Drug discovery     Volume:  2     ISSN:  1474-1776     ISO Abbreviation:  Nat Rev Drug Discov     Publication Date:  2003 Jul 
Date Detail:
Created Date:  2003-06-19     Completed Date:  2003-07-22     Revised Date:  2013-11-25    
Medline Journal Info:
Nlm Unique ID:  101124171     Medline TA:  Nat Rev Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  587-93     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-HIV Agents / chemical synthesis*
HIV Envelope Protein gp41
Peptide Fragments / chemical synthesis*
Reg. No./Substance:
0/Anti-HIV Agents; 0/HIV Envelope Protein gp41; 0/Peptide Fragments; 19OWO1T3ZE/enfuvirtide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The bicyclam AMD3100 story.
Next Document:  The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes.